drugset / Trial / NCT01064518

Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01064518

Phase 2 Completed 90 enrolled Revance Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to find out if an investigational drug, called RT001 Botulinum Toxin Type A Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called crow's feet, also known as lateral canthal lines.

Timeline

Start
2010-01
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic Topical

Indications